The Technology Development Board (TDB), Department of Science & Technology, Government of India, has sanctioned financial support to M/s TechInvention Lifecare Limited, Navi Mumbai for the establishment of a commercial-scale cGMP facility for the production of an indigenously developed 16-valent Pneumococcal Conjugate Vaccine (PCV-16).
The supported project aims to strengthen India's capability in next-generation conjugate vaccines and reduce long-term dependence on imported products through domestic innovation and manufacturing. The PCV-16 technology is built on a strategically selected panel of 16 pneumococcal serotypes, representing strains most associated with invasive pneumococcal disease (IPD), antimicrobial resistance and high fatality risks in India and other low- and middle-income countries.
The project reflects a science-based re-evaluation of serotype prioritisation, designed to support cost-effective immunisation for children, the elderly and vulnerable populations. The early upstream and downstream development was conducted at TechInvention's BSL-2 facility within the BSC BioNEST Bio-Incubator, RCB Faridabad, and later advanced to the company's GMP-aligned high-containment R&D centre, 'HORIZON', in Navi Mumbai. An Indian patent has been filed to safeguard the unique serotype design and process innovations.
With TDB's support, the project will now move towards full-scale cGMP manufacturing, ensuring that advanced conjugate vaccine technologies are developed, validated and commercialised within the country. TechInvention Lifecare Limited has demonstrated growing technical capability, held over 15 patents and working on multiple indigenous vaccine candidates, including India's first 6-in-1 meningococcal conjugate vaccine.
According to Sh. Rajesh Kumar Pathak, Secretary, TDB, the PCV-16 project represents the type of high-impact, next-generation vaccine technology that TDB aims to support.
Key Entities Referenced
Technology Development Board (TDB): An organization under the Department of Science & Technology that provides financial support to companies developing indigenous technology.
TechInvention Lifecare Ltd.: A company that is developing indigenous vaccines.
Pneumococcal Conjugate Vaccine (PCV-16): An indigenously developed 16-valent pneumococcal conjugate vaccine.
Navi Mumbai: Location of TechInvention Lifecare Ltd. and the intended facility for PCV-16 production.
Department of Science & Technology: Ministry under which the Technology Development Board operates
Ministry of Science & Technology
TDB-DST extends support to M/s
TechInvention Lifecare Ltd., Navi Mumbai for
Indigenous Development of 16-Valent
Pneumococcal Conjugate Vaccine
Posted On: 21 NOV 2025 1:52PM by PIB Delhi
The Technology Development Board (TDB), Department of Science & Technology, Government of
India, has sanctioned financial support to M/s TechInvention Lifecare Limited, Navi Mumbai for the
establishment of a commercial-scale cGMP facility for the production of an indigenously developed 16-
valent Pneumococcal Conjugate Vaccine (PCV-16). The supported project aims to strengthen India’s
capability in next-generation conjugate vaccines and reduce long-term dependence on imported
products through domestic innovation and manufacturing.
The PCV-16 technology is built on a strategically selected panel of 16 pneumococcal serotypes,
representing strains most associated with invasive pneumococcal disease (IPD), antimicrobial resistance
and high fatality risks in India and other low- and middle-income countries. While 13 serotypes overlap
with existing global PCV platforms, the inclusion of three emerging serotypes—12F, 15A and 22F—
provides broader coverage against evolving non-vaccine serogroups, reinforcing the public-health value
of this indigenous approach.
The project reflects a science-based re-evaluation of serotype prioritisation, designed to support cost-
effective immunisation for children, the elderly and vulnerable populations. The early upstream and
downstream development was conducted at TechInvention’s BSL-2 facility within the BSC BioNEST
Bio-Incubator, RCB Faridabad, and later advanced to the company’s GMP-aligned high-containment
R&D centre, ‘HORIZON’, in Navi Mumbai. An Indian patent has been filed to safeguard the unique
serotype design and process innovations.
With TDB’s support, the project will now move towards full-scale cGMP manufacturing, ensuring that
advanced conjugate vaccine technologies are developed, validated and commercialised within the
country. The initiative is expected to significantly bolster India’s self-reliance in critical vaccines,
enhance domestic biomanufacturing capacity and create pathways for future multivalent platforms.
TechInvention Lifecare Limited has demonstrated growing technical capability, held over 15 patents
and working on multiple indigenous vaccine candidates, including India’s first 6-in-1 meningococcal
conjugate vaccine. The company has also been recognised by national agencies for contributions to
next-generation vaccine innovation.Speaking on the occasion, Sh. Rajesh Kumar Pathak, Secretary, TDB, stated: “The PCV-16 project
represents the type of high-impact, next-generation vaccine technology that TDB aims to support. By
enabling indigenous development and commercial-scale manufacturing, we are strengthening national
preparedness and ensuring India’s immunisation ecosystem is supported by reliable, home-grown
solutions.”
The promoters of TechInvention added: “Support from TDB will accelerate the transition of our PCV-
16 from advanced R&D to large-scale, affordable production. This partnership is central to our effort to
deliver broad-coverage vaccines tailored for India and LMICs.”
*****
NKR/AK
(Release ID: 2192438) Visitor Counter : 318
Read this release in: Urdu , ही , Marathi , Tamil